journal article·2023-04-05

Tumor Microenvironment-Responsive Nanoherb Delivery System for Synergistically Inhibition of Cancer Stem Cells

Yuanyuan Jia, Jia Sun, Jingjing Yang, Chao Chen, Zhenyu Zhang, Kaiyong Yang, Peiliang Shen, Suchen Qu, Bangshun He, Yanni Song, Xin Han

ACS Applied Materials & Interfaces· Volume 15· Issue 13
Publisher page

Abstract

Multidrug resistance in cancer stem cells (CSCs) is a major barrier to chemotherapy; hence, developing CSC-specific targeted nanocarriers for efficient drug delivery is critical. In this study, monodisperse hollow-structured MnO 2 (H-MnO 2 ) with a mesoporous shell was created for efficient targeted drug delivery. An effective therapeutic compound isoliquiritigenin (ISL) was confirmed to inhibit the lung cancer stem-cell phenotype by natural compound screening based on integrated microfluidic devices. The resultant H-MnO 2 showed a high drug-loading content of the potent CSC-targeting compound ISL and near-infrared fluorescent dye indocyanine green (ICG). In addition, H-MnO 2 was successively modified with hyaluronic acid (HA) to enhance targeting CSCs with high CD44 expression levels. The H-MnO 2 @(ICG + ISL)@HA nanocomposites displayed promising chemotherapeutic and photothermal treatment capabilities, as well as NIR-triggered drug release, which showed excellent CSC-killing effects and tumor inhibition efficacy. Meanwhile, the development of the tumor was effectively restrained by NIR-triggered phototherapy and prominent chemotherapy without obvious side effects after tail vein injection of the nanocomposites in vivo. In summary, the prepared nanocomposites accomplished synergistic cancer therapy that targets CSCs, offering a versatile platform for lung cancer diagnosis and treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150081, China

Funding

Jiangsu Provincial Department of Education · Harbin Medical University Cancer Hospital · Natural Science Foundation of Heilongjiang Province · National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Beijing MDK Public Welfare Foundation Research Fund

References (39)

Show source-provided references
1. 10.1016/j.semcancer.2019.07.02210.1016/j.semcancer.2019.07.022 ↗
2. 10.1016/j.pharmthera.2021.10798510.1016/j.pharmthera.2021.107985 ↗
3. 10.1016/j.redox.2021.10195310.1016/j.redox.2021.101953 ↗
4. 10.1038/s41392-020-00430-110.1038/s41392-020-00430-1 ↗
5. 10.1039/D0CS00379D10.1039/D0CS00379D ↗
6. 10.1038/s41392-020-0110-510.1038/s41392-020-0110-5 ↗
7. 10.1038/s41419-020-2730-710.1038/s41419-020-2730-7 ↗
8. 10.1016/j.phrs.2022.10613810.1016/j.phrs.2022.106138 ↗
9. 10.1016/j.freeradbiomed.2021.07.01910.1016/j.freeradbiomed.2021.07.019 ↗
10. 10.1016/j.phrs.2020.10523310.1016/j.phrs.2020.105233 ↗
11. 10.3390/cancers1306123610.3390/cancers13061236 ↗
12. 10.3390/antiox903022810.3390/antiox9030228 ↗
13. 10.3390/cancers1301011510.3390/cancers13010115 ↗
14. 10.1093/carcin/bgu18710.1093/carcin/bgu187 ↗
15. 10.1002/adhm.20210098510.1002/adhm.202100985 ↗
16. 10.1080/03639045.2019.157481210.1080/03639045.2019.1574812 ↗
17. 10.1002/adma.20190582310.1002/adma.201905823 ↗
18. 10.1039/D0NR03931D10.1039/D0NR03931D ↗
19. 10.1002/adma.20210921310.1002/adma.202109213 ↗
20. 10.1186/s12951-021-01142-610.1186/s12951-021-01142-6 ↗
21. 10.1021/acsami.1c1860110.1021/acsami.1c18601 ↗
22. 10.1016/j.bioactmat.2020.12.01010.1016/j.bioactmat.2020.12.010 ↗
23. 10.1002/adma.20210397810.1002/adma.202103978 ↗
24. 10.1002/advs.20190334110.1002/advs.201903341 ↗
25. 10.1007/s40820-019-0347-010.1007/s40820-019-0347-0 ↗
26. 10.1021/acsnano.1c0868910.1021/acsnano.1c08689 ↗
27. 10.1002/smll.20210716010.1002/smll.202107160 ↗
28. 10.1016/j.apsb.2021.07.02510.1016/j.apsb.2021.07.025 ↗
29. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
30. 10.1016/j.tibtech.2020.06.00310.1016/j.tibtech.2020.06.003 ↗
31. 10.1002/adhm.20190004710.1002/adhm.201900047 ↗
32. 10.1016/j.bioactmat.2020.08.01910.1016/j.bioactmat.2020.08.019 ↗
33. 10.1002/adhm.20190152810.1002/adhm.201901528 ↗
34. 10.1002/adma.20210599910.1002/adma.202105999 ↗
35. 10.1002/adma.20210639010.1002/adma.202106390 ↗
36. 10.1021/acsnano.1c1059010.1021/acsnano.1c10590 ↗
37. 10.1016/j.apsb.2020.09.01610.1016/j.apsb.2020.09.016 ↗
38. 10.1038/s41568-020-0263-010.1038/s41568-020-0263-0 ↗
39. 10.1021/acsnano.1c0545210.1021/acsnano.1c05452 ↗